Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 155.63B | 155.63B | 134.43B | 159.46B | 142.20B | 106.72B |
Gross Profit | 44.16B | 44.16B | 38.04B | 46.40B | 40.89B | 28.77B |
EBITDA | 25.50B | 26.73B | 20.31B | 28.37B | 24.09B | 13.44B |
Net Income | 13.52B | 13.52B | 8.34B | 14.79B | 12.57B | 5.27B |
Balance Sheet | ||||||
Total Assets | 210.87B | 210.87B | 208.28B | 185.63B | 172.51B | 152.73B |
Cash, Cash Equivalents and Short-Term Investments | 35.33B | 35.33B | 28.30B | 28.57B | 34.53B | 36.38B |
Total Debt | 35.80B | 35.80B | 37.53B | 18.63B | 17.89B | 20.41B |
Total Liabilities | 74.34B | 74.34B | 79.19B | 65.90B | 62.94B | 55.11B |
Stockholders Equity | 136.52B | 136.52B | 129.10B | 119.73B | 109.57B | 97.50B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 13.47B | -12.99B | -702.00M | 4.12B | 14.56B |
Operating Cash Flow | 0.00 | 19.17B | 7.60B | 11.05B | 12.35B | 17.52B |
Investing Cash Flow | 0.00 | -6.06B | -20.23B | -12.79B | -8.54B | -2.79B |
Financing Cash Flow | 0.00 | -6.18B | 13.05B | -5.74B | -6.26B | 2.42B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
86 Outperform | ¥229.84B | 11.09 | 8.52% | 3.97% | 2.48% | -2.06% | |
81 Outperform | ¥188.67B | 15.06 | 8.64% | 1.99% | 18.08% | -18.15% | |
77 Outperform | ¥269.42B | 17.96 | ― | 2.86% | 10.24% | 49.97% | |
75 Outperform | ¥266.77B | 14.87 | 13.09% | 2.30% | 5.25% | 25.21% | |
73 Outperform | ¥245.52B | 20.56 | 15.10% | 1.09% | 15.05% | 38.95% | |
73 Outperform | ¥185.23B | 14.27 | ― | 2.82% | 10.27% | 35.69% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
CKD Corporation reported a decline in its financial performance for the three months ended June 30, 2025, with net sales decreasing by 4.8% and operating profit dropping by 13.6% compared to the previous year. Despite this, the company maintains a stable financial position with a capital adequacy ratio of 65.1%, and it plans to hold a briefing session for institutional investors and analysts to discuss these results.
The most recent analyst rating on (JP:6407) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.
CKD Corporation has completed the disposal of treasury stock as restricted stock compensation to three directors, following a board resolution on June 20, 2025. The disposal involved 16,978 shares at a price of 2,350 yen per share, totaling 39,898,300 yen, with restrictions on transferring the shares until a semiannual securities report is filed.
The most recent analyst rating on (JP:6407) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.
CKD Corporation has announced the disposal of treasury stock as restricted stock compensation to its directors, aiming to align their interests with shareholders and incentivize long-term corporate value growth. This move reflects the company’s strategy to enhance its market position by ensuring that directors are motivated to contribute to the company’s sustained success, potentially impacting stakeholders positively by aligning management’s goals with shareholder interests.
The most recent analyst rating on (JP:6407) stock is a Buy with a Yen3400.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.
CKD Corporation announced corrections to its Consolidated Financial Results for the fiscal year ended March 31, 2025. The revisions, which include updated numerical data, are intended to provide more accurate financial information. These corrections could impact stakeholders’ understanding of the company’s financial health and operational efficiency.
The most recent analyst rating on (JP:6407) stock is a Buy with a Yen3400.00 price target. To see the full list of analyst forecasts on CKD Corporation stock, see the JP:6407 Stock Forecast page.